The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).

Tim H. Brummendorf

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer

Honoraria - Bristol-Myers Squibb; Novartis; Pfizer

Research Funding - Novartis

Carlo Gambacorti-Passerini

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer

Research Funding - Pfizer

Philippe Schafhausen

Consultant or Advisory Role - Pfizer

Honoraria - Pfizer

Hanna Jean Khoury

Consultant or Advisory Role - Pfizer

Andreas Hochhaus

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Thomas Kindler

No relevant relationships to disclose

Thomas Fischer

Other Remuneration - Wyeth

Nadine Besson

Employment or Leadership Position - Pfizer

Eric Leip

Employment or Leadership Position - Pfizer

Virginia Kelly

Employment or Leadership Position - Pfizer

Jorge E. Cortes

Consultant or Advisory Role - ARIAD; ARIAD; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Pfizer; Pfizer

Research Funding - ARIAD; ARIAD; Bristol-Myers Squibb; Bristol-Myers Squibb; Deciphera; Deciphera; Novartis; Novartis; Pfizer; Pfizer